A Phase III Study of Atezolizumab plus Chemotherapy with or without Tiragolumab Immunotherapy in Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Share
Print

Full Title

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab plus Carboplatin and Etoposide with or without Tiragolumab (ANTI-TIGIT Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer (WIRB)

Purpose

The purpose of this study is to compare the effectiveness of atezolizumab plus chemotherapy with or without the investigational immunotherapy drug tiragolumab in patients newly diagnosed with extensive-stage small cell lung cancer (SCLC). Tiragolumab boosts the immune system’s ability to fight cancer by inhibiting a protein called TIGIT.

Patients will be randomly assigned to receive atezolizumab, carboplatin, and etoposide with either tiragolumab or a placebo. Atezolizumab is another form of immunotherapy and is already used to treat extensive-stage SCLC. All of the medications in this study are given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have extensive-stage SCLC and may not have previously received treatment for this cancer.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Charles Rudin at 646-608-2870.

Protocol

20-097

Phase

III

Investigator

Co-Investigators